SCHEMBL3986159

SCHEMBL3986159

COC(=O)[C@@H](N)CS(=O)(=O)Cc1cnccn1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
NAMPT P43490 2/20 0.33
CYP2C9 P11712 1/20 0.33
HPGDS O60760 1/20 0.33
NLRP3 Q96P20 3/20 0.33
CYP1A2 P05177 1/20 0.33
MEN1 O00255 1/20 0.33
LMNA P02545 1/20 0.33
KMT2A Q03164 1/20 0.33
VNN1 O95497 1/20 0.32
RAB9A P51151 2/20 0.32
KDM4E B2RXH2 1/20 0.32
SYK P43405 1/20 0.31
XDH P47989 1/20 0.31
TXNRD1 Q16881 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3986157 1.00 HDAC3 (0.34) HDAC3HDAC1HDAC2HDAC6NAMPT
SCHEMBL21946221 0.80 NLRP3 (0.41) HDAC3HDAC1HDAC2HDAC6HPGDS
Hydrochloric Acid SCHEMBL28362858 0.79 NLRP3 (0.40) HDAC3HDAC1HDAC2HDAC6HPGDS
Hydrochloric Acid SCHEMBL28362857 0.79 NLRP3 (0.40) HDAC3HDAC1HDAC2HDAC6HPGDS
SCHEMBL3980233 0.77 REN (0.36) SYK
SCHEMBL3980235 0.77 REN (0.36) SYK
SCHEMBL27254870 0.75 XDH (0.38) HDAC3HDAC1HDAC2HDAC6NAMPT
SCHEMBL3982451 0.70 PPARA (0.39) TSHR
SCHEMBL3982445 0.70 PPARA (0.39) TSHR
SCHEMBL29201451 0.69 XDH (0.40) HDAC3HDAC1HDAC2HDAC6NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663958-B1 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY INC (US) 2015-02-25 EP disclosed
US-7547701-B2 Haloalkyl containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2009-06-16 US disclosed
EP-1663958-A2 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2006-06-07 EP disclosed
US-20050182096-A1 Haloalkyl containing compounds as cysteine protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-08-18 US disclosed
WO-2005028429-A2 HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050182096-A1 Haloalkyl containing compounds as cysteine protease inhibitors CTSF, CTSS, CTSE HDAC3 1226/4885HDAC1 1463/4885HDAC2 1429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.